| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
| (30) |
Priority: |
01.04.2011 US 201161471036 P
|
| (43) |
Date of publication of application: |
|
12.02.2014 Bulletin 2014/07 |
| (60) |
Divisional application: |
|
19203410.6 |
| (73) |
Proprietor: Genentech, Inc. |
|
South San Francisco, CA 94080-4990 (US) |
|
| (72) |
Inventors: |
|
- LIN, Kui
South San Francisco
California 94080-4990 (US)
- PUNNOOSE, Elizabeth
South San Francisco
California 94080-4990 (US)
- SESHAGIRI, Somasekar
South San Francisco
California 94080-4990 (US)
|
| (74) |
Representative: Mewburn Ellis LLP |
|
City Tower
40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB) |
| (56) |
References cited: :
WO-A2-2008/049022
US-A1- 2009 028 855
|
US-A1- 2006 142 178
US-A1- 2011 038 862
|
|
| |
|
|
- Josep Tabernero ET AL: "Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel
selective ATP competitive Akt inhibitor", , 9 March 2011 (2011-03-09), XP055153957,
Retrieved from the Internet: URL:http://www.arraybiopharma.com/files/20 13/9810/8011/PubAttachment437.pdf
[retrieved on 2014-11-19]
- LIN K ET AL: "79 Preclinical characterization of GDC-0068, a novel selective ATP competitive
inhibitor of Akt", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol.
8, no. 7, 1 November 2010 (2010-11-01), page 33, XP027497767, ISSN: 1359-6349, DOI:
10.1016/S1359-6349(10)71784-5 [retrieved on 2010-11-01]
- MARGRITH E MATTMANN ET AL: "Inhibition of Akt with small molecules and biologics:
historical perspective and current status of the patent landscape/x-ms-", EXPERT OPINION
ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 21, no. 9, 1 January 2011 (2011-01-01),
pages 1309-1338, XP008159752, ISSN: 1354-3776, DOI: 10.1517/13543776.2011.587959
- A Cervantes ET AL: "Results of the First-in-human Phase I Study of GDC-0068, an Akt
Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in
Patients (pts) with Advanced Solid Tumors", , no. 619 9 November 2012 (2012-11-09),
XP055153817, Retrieved from the Internet: URL:http://ac.els-cdn.com/S095980491272416
4/1-s2.0-S0959804912724164-main.pdf?_tid=c f218536-6fc1-11e4-9243-00000aab0f6b&acdnat
=1416384072_c6a32af2864559b484a7273ad71c8a bc [retrieved on 2014-11-19]
- BARNETT ET AL.: 'Identification and characterization of pleckstrin-homology-domaindependent
and isoenzyme-specific Akt inhibitors' BIOCHEM. J. vol. 385, 2005, pages 399 - 408,
XP055060694
- OKUZUMI ET AL.: 'Inhibitor Hijacking of Akt Activation' NAT. CHEM. BIOL. vol. 5, no.
7, July 2009, pages 484 - 493, XP055093045
- SKORSKI ET AL.: 'Transformation of hematopoietic cells by BCR/ABL requires activation
of a PI- 3K/Akt-dependent pathway' EMBO J. vol. 16, no. 20, 1997, pages 6151 - 6161,
XP055093052
- KIM ET AL.: 'Mutational analysis of oncogenic AKT E17K mutation in common solid cancers
and acute leukaemias' BR. J. CANCER vol. 98, 2008, pages 1533 - 1535, XP055091514
- MAHADEVAN ET AL.: 'Discovery of a novel class of AKT pleckstrin homology domain inhibitors'
MOL. CAN. THER. vol. 7, no. 9, September 2008, pages 2621 - 2632, XP055091519
|
|
